

# Gordon C Jayson

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/6470672/gordon-c-jayson-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

200  
papers

15,426  
citations

58  
h-index

121  
g-index

215  
ext. papers

17,361  
ext. citations

7.8  
avg. IF

6.26  
L-index

#	Paper	IF	Citations
200	A phase 3 trial of bevacizumab in ovarian cancer. <i>New England Journal of Medicine</i> , <b>2011</b> , 365, 2484-96	59.2	1454
199	Ovarian cancer. <i>Lancet, The</i> , <b>2014</b> , 384, 1376-88	40	1123
198	Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. <i>Lancet, The</i> , <b>2015</b> , 386, 249-57	40	705
197	Imaging biomarker roadmap for cancer studies. <i>Nature Reviews Clinical Oncology</i> , <b>2017</b> , 14, 169-186	19.4	532
196	Antiangiogenic therapy in oncology: current status and future directions. <i>Lancet, The</i> , <b>2016</b> , 388, 518-29	40	507
195	Experimentally-derived functional form for a population-averaged high-temporal-resolution arterial input function for dynamic contrast-enhanced MRI. <i>Magnetic Resonance in Medicine</i> , <b>2006</b> , 56, 993-1000	4.4	501
194	Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. <i>Journal of the National Cancer Institute</i> , <b>2004</b> , 96, 1682-91	9.7	497
193	Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. <i>Lancet Oncology, The</i> , <b>2015</b> , 16, 928-36	21.7	475
192	The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. <i>British Journal of Cancer</i> , <b>2005</b> , 92, 1599-610	8.7	443
191	DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. <i>British Journal of Cancer</i> , <b>2007</b> , 96, 189-95	8.7	408
190	Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. <i>Lancet, The</i> , <b>2010</b> , 376, 1155-63	40	393
189	Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies. <i>Nature Reviews Clinical Oncology</i> , <b>2012</b> , 9, 167-77	19.4	275
188	Imaging tumor vascular heterogeneity and angiogenesis using dynamic contrast-enhanced magnetic resonance imaging. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 3449-59	12.9	259
187	Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. <i>Journal of the National Cancer Institute</i> , <b>2002</b> , 94, 1484-93	9.7	246
186	Intra-tumoural microvessel density in human solid tumours. <i>British Journal of Cancer</i> , <b>2002</b> , 86, 1566-77	8.7	229
185	Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. <i>British Journal of Cancer</i> , <b>2010</b> , 102, 8-18	8.7	189
184	Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 3798-804	2.2	182

183	Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet, The</i> , <b>2016</b> , 387, 1066-1074	4.0	170
182	Molecular phenotyping of a UK population: defining the human serum metabolome. <i>Metabolomics</i> , <b>2015</b> , 11, 9-26	4.7	167
181	Prospective evaluation of oral mucositis in patients receiving myeloablative conditioning regimens and haemopoietic progenitor rescue. <i>British Journal of Haematology</i> , <b>2000</b> , 110, 292-9	4.5	161
180	Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 973-81	2.2	158
179	Heparan sulfate proteoglycans and cancer. <i>British Journal of Cancer</i> , <b>2001</b> , 85, 1094-8	8.7	144
178	Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 6674-82	12.9	124
177	Phase I evaluation of a fully human anti-alpha v integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 2128-35	12.9	124
176	Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer. <i>Annals of Oncology</i> , <b>2011</b> , 22, 2036-2041	10.3	121
175	Quantitative imaging biomarkers in the clinical development of targeted therapeutics: current and future perspectives. <i>Lancet Oncology, The</i> , <b>2008</b> , 9, 766-76	21.7	121
174	Antiangiogenic therapy--evolving view based on clinical trial results. <i>Nature Reviews Clinical Oncology</i> , <b>2012</b> , 9, 297-303	19.4	120
173	Social support, anxiety and depression after chemotherapy for ovarian cancer: a prospective study. <i>British Journal of Health Psychology</i> , <b>2004</b> , 9, 569-81	8.3	117
172	Reproducibility of quantitative dynamic contrast-enhanced MRI in newly presenting glioma. <i>British Journal of Radiology</i> , <b>2003</b> , 76, 153-62	3.4	116
171	Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer. <i>Clinical Cancer Research</i> , <b>2004</b> , 10, 5178-86	12.9	115
170	DCE-MRI biomarkers of tumour heterogeneity predict CRC liver metastasis shrinkage following bevacizumab and FOLFOX-6. <i>British Journal of Cancer</i> , <b>2011</b> , 105, 139-45	8.7	114
169	Molecular imaging of antiangiogenic agents. <i>Oncologist</i> , <b>2005</b> , 10, 92-103	5.7	114
168	Assessment of antiangiogenic and antivascular therapeutics using MRI: recommendations for appropriate methodology for clinical trials. <i>British Journal of Radiology</i> , <b>2003</b> , 76 Spec No 1, S87-91	3.4	109
167	Heparan sulfate undergoes specific structural changes during the progression from human colon adenoma to carcinoma in vitro. <i>Journal of Biological Chemistry</i> , <b>1998</b> , 273, 51-7	5.4	106
166	A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion. <i>British Journal of Cancer</i> , <b>1995</b> , 72, 461-8	8.7	106

165	Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. <i>Lancet Oncology, The</i> , <b>2018</b> , 19, 1680-1687	21.7	105
164	The current and future management of malignant ascites. <i>Clinical Oncology</i> , <b>2003</b> , 15, 59-72	2.8	102
163	Platelet-derived growth factor receptor (PDGFR): a target for anticancer therapeutics. <i>Drug Resistance Updates</i> , <b>2005</b> , 8, 75-83	23.2	100
162	Preliminary study of oxygen-enhanced longitudinal relaxation in MRI: a potential novel biomarker of oxygenation changes in solid tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2009</b> , 75, 1209-15	4	95
161	Carcinomatous meningitis in patients with breast cancer. An aggressive disease variant. <i>Cancer</i> , <b>1994</b> , 74, 3135-41	6.4	93
160	Heparin oligosaccharides: inhibitors of the biological activity of bFGF on Caco-2 cells. <i>British Journal of Cancer</i> , <b>1997</b> , 75, 9-16	8.7	89
159	Carcinosarcoma of the ovary. <i>British Journal of Cancer</i> , <b>2003</b> , 88, 654-7	8.7	82
158	Alpha-v integrins as therapeutic targets in oncology. <i>Cancer Investigation</i> , <b>2007</b> , 25, 632-46	2.1	80
157	Vascular endothelial growth factors C and D and lymphangiogenesis in gastrointestinal tract malignancy. <i>British Journal of Cancer</i> , <b>2003</b> , 89, 426-30	8.7	80
156	Antiangiogenic drugs in ovarian cancer. <i>British Journal of Cancer</i> , <b>2009</b> , 100, 1-7	8.7	78
155	Breath-hold perfusion and permeability mapping of hepatic malignancies using magnetic resonance imaging and a first-pass leakage profile model. <i>NMR in Biomedicine</i> , <b>2002</b> , 15, 164-73	4.4	75
154	Quantitative angiogenesis assays in vivo--a review. <i>Angiogenesis</i> , <b>2004</b> , 7, 1-16	10.6	73
153	A review of the latest clinical compounds to inhibit VEGF in pathological angiogenesis. <i>Expert Opinion on Therapeutic Targets</i> , <b>2006</b> , 10, 867-76	6.4	71
152	Carcinomatous meningitis in solid tumours. <i>Annals of Oncology</i> , <b>1996</b> , 7, 773-86	10.3	70
151	Comparison of normal tissue R1 and R*2 modulation by oxygen and carbogen. <i>Magnetic Resonance in Medicine</i> , <b>2009</b> , 61, 75-83	4.4	69
150	Inhibition of FGFR2 and FGFR1 increases cisplatin sensitivity in ovarian cancer. <i>Cancer Biology and Therapy</i> , <b>2010</b> , 10, 495-504	4.6	67
149	The clinical development of the bryostatins. <i>Anti-Cancer Drugs</i> , <b>2002</b> , 13, 673-83	2.4	67
148	Phase I evaluation of CDP791, a PEGylated di-Fab' conjugate that binds vascular endothelial growth factor receptor 2. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 7113-8	12.9	65

147	A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors. <i>Annals of Oncology</i> , <b>2011</b> , 22, 1413-1419	10.3	63
146	Organ-specific effects of oxygen and carbogen gas inhalation on tissue longitudinal relaxation times. <i>Magnetic Resonance in Medicine</i> , <b>2007</b> , 58, 490-6	4.4	61
145	Tracer kinetic model-driven registration for dynamic contrast-enhanced MRI time-series data. <i>Magnetic Resonance in Medicine</i> , <b>2007</b> , 58, 1010-9	4.4	59
144	Method validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAP. <i>British Journal of Cancer</i> , <b>2006</b> , 95, 42-8	8.7	59
143	Making the longest sugars: a chemical synthesis of heparin-related [4] oligosaccharides from 16-mer to 40-mer. <i>Chemical Science</i> , <b>2015</b> , 6, 6158-6164	9.4	58
142	Targeted anti-vascular therapies for ovarian cancer: current evidence. <i>British Journal of Cancer</i> , <b>2013</b> , 108, 250-8	8.7	58
141	Vascular endothelial growth factors and receptors in colorectal cancer: implications for anti-angiogenic therapy. <i>European Journal of Cancer</i> , <b>2006</b> , 42, 112-7	7.5	58
140	Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of Canada clinical trials group. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 1859-66	2.2	57
139	Heparin octasaccharides inhibit angiogenesis in vivo. <i>Clinical Cancer Research</i> , <b>2005</b> , 11, 8172-9	12.9	56
138	The combination of circulating Ang1 and Tie2 levels predicts progression-free survival advantage in bevacizumab-treated patients with ovarian cancer. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 4549-4558	12.9	55
137	Hypoxia increases heparanase-dependent tumor cell invasion, which can be inhibited by antiheparanase antibodies. <i>Cancer Research</i> , <b>2004</b> , 64, 3928-33	10.1	55
136	Predicting response to bevacizumab in ovarian cancer: a panel of potential biomarkers informing treatment selection. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 5227-39	12.9	54
135	Endothelial heparan sulfate 6-O-sulfation levels regulate angiogenic responses of endothelial cells to fibroblast growth factor 2 and vascular endothelial growth factor. <i>Journal of Biological Chemistry</i> , <b>2012</b> , 287, 36132-46	5.4	54
134	Quantitative multiplexed quantum dot immunohistochemistry. <i>Biochemical and Biophysical Research Communications</i> , <b>2008</b> , 374, 181-6	3.4	51
133	Review of recent trials of chemotherapy for advanced breast cancer: the taxanes. <i>European Journal of Cancer</i> , <b>1997</b> , 33, 2183-93	7.5	50
132	Phase I investigation of recombinant anti-human vascular endothelial growth factor antibody in patients with advanced cancer. <i>European Journal of Cancer</i> , <b>2005</b> , 41, 555-63	7.5	49
131	A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma. <i>British Journal of Cancer</i> , <b>2001</b> , 84, 465-9	8.7	49
130	Lymphatic vessel density, microvessel density and lymphangiogenic growth factor expression in colorectal cancer. <i>Colorectal Disease</i> , <b>2007</b> , 9, 793-800	2.1	48

129	PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2018</b> , 81, 647-658	3.5	47
128	Synthetic heparan sulfate oligosaccharides inhibit endothelial cell functions essential for angiogenesis. <i>PLoS ONE</i> , <b>2010</b> , 5, e11644	3.7	47
127	Do imaging biomarkers relate to outcome in patients treated with VEGF inhibitors?. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 6588-98	12.9	46
126	First gram-scale synthesis of a heparin-related dodecasaccharide. <i>Organic Letters</i> , <b>2013</b> , 15, 88-91	6.2	42
125	Tetrasaccharide iteration synthesis of a heparin-like dodecasaccharide and radiolabelling for in vivo tissue distribution studies. <i>Nature Communications</i> , <b>2013</b> , 4, 2016	17.4	42
124	Immunomodulation in patients receiving intravenous Bryostatin 1 in a phase I clinical study: comparison with effects of Bryostatin 1 on lymphocyte function in vitro. <i>Cancer Immunology, Immunotherapy</i> , <b>1994</b> , 39, 223-30	7.4	42
123	Ovarian cancer cell heparan sulfate 6-O-sulfotransferases regulate an angiogenic program induced by heparin-binding epidermal growth factor (EGF)-like growth factor/EGF receptor signaling. <i>Journal of Biological Chemistry</i> , <b>2014</b> , 289, 10488-10501	5.4	41
122	A longitudinal investigation of psychological morbidity in patients with ovarian cancer. <i>British Journal of Cancer</i> , <b>2008</b> , 99, 1794-801	8.7	41
121	Heparan sulphate synthetic and editing enzymes in ovarian cancer. <i>British Journal of Cancer</i> , <b>2007</b> , 96, 1544-8	8.7	41
120	Phase II trial of tamoxifen and goserelin in recurrent epithelial ovarian cancer. <i>British Journal of Cancer</i> , <b>2005</b> , 93, 647-51	8.7	41
119	Chemotherapy or upfront surgery for newly diagnosed advanced ovarian cancer: Results from the MRC CHORUS trial.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 5500-5500	2.2	41
118	Outcomes after multiple lines of chemotherapy for platinum-resistant epithelial cancers of the ovary, peritoneum, and fallopian tube. <i>International Journal of Gynecological Cancer</i> , <b>2011</b> , 21, 58-65	3.5	40
117	Inhibition of carboplatin-induced DNA interstrand cross-link repair by gemcitabine in patients receiving these drugs for platinum-resistant ovarian cancer. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 4899-905	12.9	40
116	The clinical potential of antiangiogenic fragments of extracellular matrix proteins. <i>British Journal of Cancer</i> , <b>2005</b> , 93, 967-72	8.7	40
115	Comparison of the performance of tracer kinetic model-driven registration for dynamic contrast enhanced MRI using different models of contrast enhancement. <i>Academic Radiology</i> , <b>2006</b> , 13, 1112-23	4.3	39
114	VEGF antagonists. <i>Expert Opinion on Biological Therapy</i> , <b>2001</b> , 1, 703-18	5.4	39
113	Binding of endostatin to endothelial heparan sulphate shows a differential requirement for specific sulphates. <i>Biochemical Journal</i> , <b>2003</b> , 375, 131-9	3.8	38
112	ZD1839 (IRESSA): a selective EGFR-TK inhibitor. <i>Expert Review of Anticancer Therapy</i> , <b>2002</b> , 2, 161-8	3.5	38

111	Coordinated modulation of the fibroblast growth factor dual receptor mechanism during transformation from human colon adenoma to carcinoma. <i>International Journal of Cancer</i> , <b>1999</b> , 82, 298-304	7.5	38
110	Scalable synthesis of L-iduronic acid derivatives via stereocontrolled cyanohydrin reaction for synthesis of heparin-related disaccharides. <i>Organic Letters</i> , <b>2009</b> , 11, 4528-31	6.2	37
109	Thrombosis in ovarian cancer: a case control study. <i>British Journal of Cancer</i> , <b>2014</b> , 110, 1118-24	8.7	36
108	Synthesis and scalable conversion of L-iduronamides to heparin-related di- and tetrasaccharides. <i>Journal of Organic Chemistry</i> , <b>2012</b> , 77, 7823-43	4.2	36
107	The treatment of nephrotic syndrome caused by primary (light chain) amyloid with vincristine, doxorubicin and dexamethasone. <i>British Journal of Cancer</i> , <b>1998</b> , 78, 774-6	8.7	33
106	An Updated Synthesis of the Diazo-Transfer Reagent Imidazole-1-sulfonyl Azide Hydrogen Sulfate. <i>Journal of Organic Chemistry</i> , <b>2016</b> , 81, 3443-6	4.2	33
105	A living biobank of ovarian cancer ex vivo models reveals profound mitotic heterogeneity. <i>Nature Communications</i> , <b>2020</b> , 11, 822	17.4	32
104	'Fit-for-purpose' validation of SearchLight multiplex ELISAs of angiogenesis for clinical trial use. <i>Journal of Immunological Methods</i> , <b>2009</b> , 342, 106-14	2.5	32
103	p53 and related proteins in epithelial ovarian cancer. <i>European Journal of Cancer</i> , <b>2000</b> , 36, 2317-28	7.5	32
102	Plasma Tie2 is a tumor vascular response biomarker for VEGF inhibitors in metastatic colorectal cancer. <i>Nature Communications</i> , <b>2018</b> , 9, 4672	17.4	32
101	Efficient chemical synthesis of heparin-like octa-, deca- and dodecasaccharides and inhibition of FGF2- and VEGF165-mediated endothelial cell functions. <i>Chemical Science</i> , <b>2013</b> , 4, 3218	9.4	31
100	A phase II trial of bryostatin-1 administered by weekly 24-hour infusion in recurrent epithelial ovarian carcinoma. <i>British Journal of Cancer</i> , <b>2003</b> , 89, 1152-4	8.7	31
99	Synthetic heparan sulfate dodecasaccharides reveal single sulfation site interconverts CXCL8 and CXCL12 chemokine biology. <i>Chemical Communications</i> , <b>2015</b> , 51, 13846-9	5.8	30
98	A randomized phase II trial of interleukin 2 and interleukin 2-interferon alpha in advanced renal cancer. <i>British Journal of Cancer</i> , <b>1998</b> , 78, 366-9	8.7	30
97	A phase 1 trial of intravenous 4-(N-(S-glutathionylacetyl)amino) phenylarsenoxide (GSAO) in patients with advanced solid tumours. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2013</b> , 72, 1343-52	3.5	28
96	A longitudinal investigation of posttraumatic stress disorder in patients with ovarian cancer. <i>Journal of Psychosomatic Research</i> , <b>2011</b> , 70, 422-31	4.1	27
95	Doctor, does this mean I'm going to starve to death?. <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 199-201	2.2	26
94	Regulation of fibroblast growth factor-2 activity by human ovarian cancer tumor endothelium. <i>Clinical Cancer Research</i> , <b>2005</b> , 11, 4282-8	12.9	26



93	Identification of early predictive imaging biomarkers and their relationship to serological angiogenic markers in patients with ovarian cancer with residual disease following cytotoxic therapy. <i>Annals of Oncology</i> , <b>2010</b> , 21, 1982-1989	10.3	25
92	A phase II trial evaluating two schedules of sagopilone (ZK-EPO), a novel epothilone, in patients with platinum-resistant ovarian cancer. <i>Annals of Oncology</i> , <b>2011</b> , 22, 2411-2416	10.3	23
91	Is the toxicity of anti-angiogenic drugs predictive of outcome? A review of hypertension and proteinuria as biomarkers of response to anti-angiogenic therapy. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2012</b> , 8, 283-93	5.5	22
90	Angiogenesis as a target for the treatment of ovarian cancer. <i>Current Opinion in Oncology</i> , <b>2013</b> , 25, 558-65	4.5	22
89	A two-part phase II study of cediranib in patients with advanced solid tumours: the effect of food on single-dose pharmacokinetics and an evaluation of safety, efficacy and imaging pharmacodynamics. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2011</b> , 68, 631-41	3.5	22
88	Imaging angiogenesis of genitourinary tumors. <i>Nature Reviews Urology</i> , <b>2010</b> , 7, 69-82	5.5	22
87	Enhancing fraction predicts clinical outcome following first-line chemotherapy in patients with epithelial ovarian carcinoma. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 6130-5	12.9	22
86	Small-molecule-induced clustering of heparan sulfate promotes cell adhesion. <i>Journal of the American Chemical Society</i> , <b>2013</b> , 135, 11032-9	16.4	21
85	Resistance to anti-VEGF agents. <i>Current Pharmaceutical Design</i> , <b>2004</b> , 10, 51-64	3.3	20
84	Palliative home parenteral nutrition in patients with ovarian cancer and malignant bowel obstruction: experiences of women and family caregivers. <i>BMC Palliative Care</i> , <b>2019</b> , 18, 120	3	20
83	Segregation of late outgrowth endothelial cells into functional endothelial CD34- and progenitor-like CD34+ cell populations. <i>Angiogenesis</i> , <b>2015</b> , 18, 47-68	10.6	19
82	DCE-MRI model selection for investigating disruption of microvascular function in livers with metastatic disease. <i>Journal of Magnetic Resonance Imaging</i> , <b>2012</b> , 35, 196-203	5.6	19
81	Evaluation of hypertension and proteinuria as markers of efficacy in antiangiogenic therapy for metastatic colorectal cancer. <i>Journal of Clinical Gastroenterology</i> , <b>2014</b> , 48, 430-4	3	19
80	Heparanase gene haplotype (CGC) is associated with stage of disease in patients with ovarian carcinoma. <i>Cancer Science</i> , <b>2007</b> , 98, 844-9	6.9	19
79	Preclinical evaluation of the pharmacodynamic properties of 2,5-diaziridinyl-3-hydroxymethyl-6-methyl-1,4-benzoquinone. <i>Clinical Cancer Research</i> , <b>2005</b> , 11, 2695-701	12.9	19
78	Systematic analysis of circulating soluble angiogenesis-associated proteins in ICON7 identifies Tie2 as a biomarker of vascular progression on bevacizumab. <i>British Journal of Cancer</i> , <b>2016</b> , 115, 228-35	8.7	19
77	Randomised phase II study of cisplatin-etoposide versus infusional carboplatin in advanced non-small-cell lung cancer and mesothelioma. <i>Annals of Oncology</i> , <b>2000</b> , 11, 201-6	10.3	18
76	Oligosaccharides as anti-angiogenic agents. <i>Expert Opinion on Biological Therapy</i> , <b>2008</b> , 8, 351-62	5.4	17



75	New therapeutic agents in ovarian cancer. <i>Current Opinion in Obstetrics and Gynecology</i> , <b>2009</b> , 21, 44-53	2.4	16
74	The interval from surgery to chemotherapy in the treatment of advanced epithelial ovarian carcinoma. <i>European Journal of Surgical Oncology</i> , <b>2006</b> , 32, 588-91	3.6	15
73	An audit of primary surgical treatment for women with ovarian cancer referred to a cancer centre. <i>British Journal of Cancer</i> , <b>1999</b> , 80, 444-7	8.7	15
72	Better life expectancy in women with BRCA2 compared with BRCA1 mutations is attributable to lower frequency and later onset of ovarian cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2008</b> , 17, 1535-42	4	14
71	Synthesis of a heparin-related GlcN-IdoA sulfation-site variable disaccharide library and analysis by Raman and ROA spectroscopy. <i>Carbohydrate Research</i> , <b>2014</b> , 400, 44-53	2.9	13
70	PARP inhibitors in BRCA mutation-associated ovarian cancer. <i>Lancet Oncology</i> , <b>2015</b> , 16, 10-2	21.7	13
69	Requirement for expert histopathological assessment of ovarian cancer and borderline tumors. <i>British Journal of Cancer</i> , <b>2000</b> , 82, 760-2	8.7	13
68	Prevalence of germline pathogenic variants in sequential epithelial ovarian cancer cases. <i>Journal of Medical Genetics</i> , <b>2019</b> , 56, 301-307	5.8	12
67	Synthesis of L-iduronic acid derivatives via [3.2.1] and [2.2.2] L-iduronic lactones from bulk glucose-derived cyanohydrin hydrolysis: a reversible conformationally switched superdisarmed/rearmed lactone route to heparin disaccharides. <i>Journal of Organic Chemistry</i> , <b>2015</b> , 80, 3777-89	4.2	12
66	Angiogenesis as a therapeutic target in cancer. <i>Clinical Medicine</i> , <b>2008</b> , 8, 455-8	1.9	12
65	A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2008</b> , 61, 579-85	3.5	12
64	Targeted antitumour therapy--future perspectives. <i>British Journal of Cancer</i> , <b>2005</b> , 92 Suppl 1, S28-31	8.7	12
63	No socioeconomic inequalities in ovarian cancer survival within two randomised clinical trials. <i>British Journal of Cancer</i> , <b>2014</b> , 111, 589-97	8.7	11
62	Issues on fit-for-purpose validation of a panel of ELISAs for application as biomarkers in clinical trials of anti-Angiogenic drugs. <i>British Journal of Cancer</i> , <b>2010</b> , 102, 1524-32	8.7	11
61	Review of recent trials of chemotherapy for advanced breast cancer: studies excluding taxanes. <i>European Journal of Cancer</i> , <b>1997</b> , 33, 2171-82	7.5	11
60	The best guess approach to phase I trial design. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 206-8	2.2	11
59	Pre-operative plasma levels of vascular endothelial growth factor A, C and D in patients with colorectal cancer. <i>Clinical Oncology</i> , <b>2005</b> , 17, 367-71	2.8	11
58	Metallothionein expression in epithelial ovarian cancer: effect of chemotherapy and prognostic significance. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2000</b> , 126, 717-21	4.9	11

57	Assessment and management of diarrhea following VEGF receptor TKI treatment in patients with ovarian cancer. <i>Gynecologic Oncology</i> , <b>2018</b> , 150, 173-179	4.9	10
56	Synthesis of [18F]fluoroacetaldehyde. Application to [18F]fluoroethylation of benzylamine under reductive alkylation conditions. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , <b>2008</b> , 51, 262-267	1.9	10
55	Oral melphalan as a treatment for platinum-resistant ovarian cancer. <i>British Journal of Cancer</i> , <b>2003</b> , 88, 1828-30	8.7	10
54	A phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), administered at two different dose schedules in patients with platinum- and taxane-resistant/refractory ovarian cancer. <i>Gynecologic Oncology</i> , <b>2004</b> , 95, 114-9	4.9	10
53	Basic fibroblast growth factor increases the multiplication and migration of a serum-free derivative of CACO-2 but does not affect differentiation. <i>Cancer Research</i> , <b>1994</b> , 54, 5718-23	10.1	10
52	First-Line Management of Advanced High-Grade Serous Ovarian Cancer. <i>Current Oncology Reports</i> , <b>2020</b> , 22, 64	6.3	9
51	A longitudinal investigation of psychological disorders in patients prior and subsequent to a diagnosis of ovarian cancer. <i>Journal of Clinical Psychology in Medical Settings</i> , <b>2010</b> , 17, 167-73	2	9
50	Antiangiogenic therapy for ovarian cancer. <i>Current Opinion in Oncology</i> , <b>2007</b> , 19, 497-505	4.2	9
49	Tracer kinetic model-driven registration for dynamic contrast enhanced MRI time series. <i>Lecture Notes in Computer Science</i> , <b>2005</b> , 8, 91-8	0.9	9
48	Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. <i>Lancet Oncology</i> , <b>2021</b> , 22, 277-288	21.7	9
47	A latent reactive handle for functionalising heparin-like and LMWH deca- and dodecasaccharides. <i>Organic and Biomolecular Chemistry</i> , <b>2015</b> , 13, 11208-19	3.9	7
46	Discharging Women with Advanced Ovarian Cancer on Home Parenteral Nutrition: Making and Implementing the Decision. <i>Nutrients</i> , <b>2020</b> , 12,	6.7	7
45	Mixed-effects modeling of clinical DCE-MRI data: application to colorectal liver metastases treated with bevacizumab. <i>Journal of Magnetic Resonance Imaging</i> , <b>2015</b> , 41, 132-41	5.6	7
44	Modular synthesis of heparin-related tetra-, hexa- and octasaccharides with differential o-6 protections: programming for regiodefined 6-o-modifications. <i>Molecules</i> , <b>2015</b> , 20, 6167-6180	4.8	7
43	High-performance liquid chromatographic assay for the novel antitumor drug, bryostatins-1, incorporating a serum extraction technique. <i>Biomedical Applications</i> , <b>1998</b> , 709, 113-7		7
42	The morphogenic properties of oligomeric endostatin are dependent on cell surface heparan sulfate. <i>Journal of Biological Chemistry</i> , <b>2006</b> , 281, 14813-22	5.4	7
41	Stage- and CA125-related survival in patients with epithelial ovarian cancer treated at a cancer center. <i>International Journal of Gynecological Cancer</i> , <b>2006</b> , 16 Suppl 1, 18-24	3.5	7
40	SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel-irinotecan as first-line therapy for ovarian cancer. <i>British Journal of Cancer</i> , <b>2006</b> , 94, 55-61	8.7	7

39	Impact of laparotomy and liver resection on the peritoneal concentrations of fibroblast growth factor 2, vascular endothelial growth factor and hepatocyte growth factor. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2006</b> , 132, 41-4	4.9	7
38	Synthetic Site-Selectively Mono-6-O-Sulfated Heparan Sulfate Dodecasaccharide Shows Anti-Angiogenic Properties In Vitro and Sensitizes Tumors to Cisplatin In Vivo. <i>PLoS ONE</i> , <b>2016</b> , 11, e0159739	3.7	7
37	Applications of Dynamic Contrast-Enhanced MRI in Oncology Drug Development <b>2005</b> , 281-297		7
36	Pazopanib and Fosbretabulin in recurrent ovarian cancer (PAZOFOS): A multi-centre, phase 1b and open-label, randomised phase 2 trial. <i>Gynecologic Oncology</i> , <b>2020</b> , 156, 545-551	4.9	6
35	The development of anti-angiogenic heparan sulfate oligosaccharides. <i>Biochemical Society Transactions</i> , <b>2014</b> , 42, 1596-600	5.1	6
34	Risky research and participants' interests: the ethics of phase 2C clinical trials. <i>Clinical Ethics</i> , <b>2011</b> , 6, 91-96	1	6
33	Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial. <i>ESMO Open</i> , <b>2021</b> , 6, 100043	6	6
32	Screening tool for malignant bowel obstruction in relapsed, metastatic ovarian cancer. <i>ESMO Open</i> , <b>2019</b> , 4, e000463	6	5
31	Dealing with loss: food and eating in women with ovarian cancer on parenteral nutrition. <i>Journal of Human Nutrition and Dietetics</i> , <b>2020</b> , 33, 550-556	3.1	5
30	Indexed distribution analysis for improved significance testing of spatially heterogeneous parameter maps: application to dynamic contrast-enhanced MRI biomarkers. <i>Magnetic Resonance in Medicine</i> , <b>2014</b> , 71, 1299-311	4.4	4
29	The ethical and scientific case for phase 2C clinical trials. <i>Lancet Oncology, The</i> , <b>2010</b> , 11, 410-1	21.7	4
28	Development of antiangiogenic agents for ovarian cancer. <i>Expert Review of Anticancer Therapy</i> , <b>2008</b> , 8, 21-32	3.5	4
27	The Role of Imaging in the Clinical Development of Antiangiogenic Agents <b>2008</b> , 525-536		4
26	Cross-visit tumor sub-segmentation and registration with outlier rejection for dynamic contrast-enhanced MRI time series data. <i>Lecture Notes in Computer Science</i> , <b>2010</b> , 13, 121-8	0.9	4
25	Amyl nitrite-mediated conversion of aromatic and heteroaromatic primary amides to carboxylic acids. <i>Tetrahedron Letters</i> , <b>2015</b> , 56, 5153-5156	2	3
24	Correlation of FGF2 tumor expression with tumor response, PFS, and changes in plasma pharmacodynamic (PD) markers following treatment with brivanib alaninate, an oral dual inhibitor of VEGFR and FGFR tyrosine kinases. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 3506-3506	2.2	3
23	Stage- and CA125-related survival in patients with epithelial ovarian cancer treated at a cancer center. <i>International Journal of Gynecological Cancer</i> , <b>2006</b> , 16, 18-24	3.5	3
22	Improved Survival from Ovarian Cancer in Patients Treated in Phase III Trial Active Cancer Centres in the UK. <i>Clinical Oncology</i> , <b>2016</b> , 28, 760-765	2.8	3

21	Dynamics of circulating vascular endothelial growth factor-A predict benefit from antiangiogenic cediranib in metastatic or recurrent cervical cancer patients. <i>British Journal of Clinical Pharmacology</i> , <b>2019</b> , 85, 1781-1789	3.8	2
20	VEGF inhibitors and advanced ovarian cancer. <i>Lancet Oncology, The</i> , <b>2011</b> , 12, 1082-3	21.7	2
19	Phase I study of CNTO 95, a fully human monoclonal antibody (mAb) to $\alpha_5\beta_1$ integrins, in patients with solid tumors. <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 3119-3119	2.2	2
18	Hypertension (HTN) and proteinuria (PTN) as biomarkers of efficacy in antiangiogenic therapy for metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, e13580-e13580	2.2	2
17	Psychosexual morbidity in women with ovarian cancer. <i>International Journal of Gynecological Cancer</i> , <b>2020</b> , 30, 1983-1989	3.5	2
16	Imaging Tumor Angiogenesis <b>2019</b> , 277-290		1
15	Novel phase I trial design to evaluate the addition of cediranib or selumetinib to preoperative chemoradiotherapy for locally advanced rectal cancer: the DREAMtherapy trial. <i>European Journal of Cancer</i> , <b>2019</b> , 117, 48-59	7.5	1
14	Dose-dense cisplatin with gemcitabine for relapsed platinum-resistant ovarian cancer. <i>International Journal of Gynecological Cancer</i> , <b>2019</b> , 29, 341-345	3.5	1
13	An Outpatient, Dose-Intense, Intravenous Cisplatin and Oral Etoposide Regimen for the Treatment of Advanced, Platinum-Resistant Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , <b>2018</b> , 28, 448-452	3.5	1
12	Biomarkers and response to bevacizumab--response. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 1058	12.9	1
11	Assessing cancer services in North West England: the Chinese population. <i>European Journal of Cancer Care</i> , <b>2014</b> , 23, 570-81	2.4	1
10	The neoadjuvant approach in the treatment of patients with advanced epithelial ovarian carcinoma. <i>Clinical Oncology</i> , <b>2007</b> , 19, 125-8	2.8	1
9	c-MET/VEGFR-2 co-localisation impacts on survival following bevacizumab therapy in epithelial ovarian cancer: an exploratory biomarker study of the phase 3 ICON7 trial.. <i>BMC Medicine</i> , <b>2022</b> , 20, 59	11.4	1
8	Effect of oxaliplatin plus 5-fluorouracil or capecitabine on circulating and imaging biomarkers in patients with metastatic colorectal cancer: a prospective biomarker study. <i>BMC Cancer</i> , <b>2021</b> , 21, 354	4.8	0
7	Vascular endothelial growth factor antagonists as anticancer agents. <i>American Journal of Cancer</i> , <b>2004</b> , 3, 229-245		
6	Profiling heparan sulfate proteoglycans in ovarian carcinoma. <i>Scientific World Journal, The</i> , <b>2005</b> , 5, 230-3.2		
5	Molecular Imaging of Targets and Therapeutics in Tumour Angiogenesis <b>2008</b> , 511-528		
4	Psychosexual Morbidity in Women With Ovarian Cancer: Evaluation by Germline BRCA Gene Mutational Status.. <i>Sexual Medicine</i> , <b>2021</b> , 10, 100465	2.7	

- 3 Vascular Endothelial Growth Factor C and Vascular Endothelial Growth Factor D: Biology, Functions and Role in Cancer **2004**, 145-162
- 2 Imaging Tumor Angiogenesis **2017**, 1-14
- 1 Novel Anti-angiogenic Therapies in Ovarian Cancer **2011**, 51-72